|
|
|
|
|
Gerri Henwood Prior to her work on the Fund, Ms. Henwood was the President and CEO of Auxilium Pharmaceuticals, Inc (NASDAQ: AUXL), a company she founded in late 1999. She raised $90 million in private equity and was able to take the company public in August 2004. As of December 31, 2006, Auxilium’s market capitalization exceeded $500 million. Ms. Henwood successfully shepherded this start-up company through the drug development stage to its current position with one drug on the market and several more in late stage development and trailing 12 month revenues exceeding $60 million.
From 1985-1999, Ms. Henwood was the founder and CEO of IBAH, a contract research organization. IBAH reached a net revenue level of $150 million, as a NASDAQ traded company, before being acquired by Omnicare in 1998.
Ms. Henwood began her career with Smith Kline & French, now part of Glaxo SmithKline PLC, in the pharmaceutical marketing department. She rose through the ranks at Smith Kline & French to be the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director – Marketing in the International Pharmaceutical Division.
Ms Henwood currently serves on the Board of Directors of Alkermes, Inc. (NASDAQ:ALKS), MAP Pharmaceuticals, Inc. (private) and is a member of the Board of Trustees for LaSalle Academy, an elementary school for “at risk” youth, in Philadelphia, PA. Ms. Henwood holds a B.S. degree from Neumann College.
|
Gerri
Henwood Dr. Abraham Ludomirski Wayne B. Weisman Jeff Dykan Winston J. Churchill Richard L. Sherman Charles C. Freyer Dennis P. Ferry |